tradingkey.logo

enVVeno Medical Corp

NVNO
0.689USD
+0.039+6.00%
Market hours ETQuotes delayed by 15 min
13.26MMarket Cap
LossP/E TTM

enVVeno Medical Corp

0.689
+0.039+6.00%

More Details of enVVeno Medical Corp Company

enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.

enVVeno Medical Corp Info

Ticker SymbolNVNO
Company nameenVVeno Medical Corp
IPO dateMay 31, 2018
CEOMr. Robert A. Berman
Number of employees37
Security typeOrdinary Share
Fiscal year-endMay 31
Address70 Doppler
CityIRVINE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92618
Phone19492612900
Websitehttps://envveno.com/
Ticker SymbolNVNO
IPO dateMay 31, 2018
CEOMr. Robert A. Berman

Company Executives of enVVeno Medical Corp

Name
Name/Position
Position
Shareholding
Change
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
11.15K
+7.73%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
11.15K
+7.73%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--

Revenue Breakdown

No Data
No Data
By Business
By Region
No Data

Shareholding Stats

Updated: Fri, Oct 31
Updated: Fri, Oct 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Kingdon Capital Management, L.L.C.
6.72%
Perceptive Advisors LLC
6.36%
The Vanguard Group, Inc.
3.45%
Nantahala Capital Management, LLC
2.94%
Westside Investment Management, LLC
1.38%
Other
79.14%
Shareholders
Shareholders
Proportion
Kingdon Capital Management, L.L.C.
6.72%
Perceptive Advisors LLC
6.36%
The Vanguard Group, Inc.
3.45%
Nantahala Capital Management, LLC
2.94%
Westside Investment Management, LLC
1.38%
Other
79.14%
Shareholder Types
Shareholders
Proportion
Hedge Fund
11.08%
Investment Advisor
7.41%
Private Equity
6.48%
Individual Investor
1.77%
Investment Advisor/Hedge Fund
1.55%
Research Firm
1.06%
Venture Capital
0.09%
Other
70.56%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
75
5.53M
27.33%
-744.33K
2025Q2
75
3.80M
19.76%
-3.06M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
2023Q2
55
2.71M
28.61%
-1.36M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Kingdon Capital Management, L.L.C.
1.36M
7.06%
+500.00K
+58.19%
Sep 02, 2025
Perceptive Advisors LLC
1.28M
6.68%
+1.28M
--
Jun 30, 2025
The Vanguard Group, Inc.
698.34K
3.63%
+97.43K
+16.21%
Jun 30, 2025
Nantahala Capital Management, LLC
594.66K
3.09%
--
--
Jun 30, 2025
Westside Investment Management, LLC
279.52K
1.45%
+20.48K
+7.90%
Jun 30, 2025
UBS O'Connor LLC
241.16K
1.25%
-54.87K
-18.54%
Jun 30, 2025
I.C.M. Investment Bank AG
200.00K
1.04%
+50.00K
+33.33%
Jun 30, 2025
Geode Capital Management, L.L.C.
199.51K
1.04%
+2.21K
+1.12%
Jun 30, 2025
J.P. Morgan Securities LLC
182.30K
0.95%
-11.91K
-6.13%
Jun 30, 2025
View more

Related ETFs

Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Date
Type
Ratio
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
KeyAI